Lung adenocarcinoma mimicking pulmonary fibrosis-a case report

Lung, Respiratory and Thoracic Cancer

Successful pulmonary arterial embolization followed by curative surgery for a lepidic predominant lung adenocarcinoma with severe hypoxemia

BMC Surg.

Sebane L, El-Hajjam M, Puyo P, Longchampt E, Giroux Leprieur E

doi: 10.1186/s12893-018-0351-1.

Lung, Respiratory and Thoracic CancerFurther Publications

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

healthbook TIMES Oncology Hematology

Astaras C, Bettini A, Betticher D.C

doi: 10.36000/hbT.OH.2020.03.01

Metastases from lung adenocarcinoma within a leiomyoma: A case report

Gynecol Oncol Rep.

Rush SK, Toukatly MN, Kilgore MR, Urban RR Author information

doi: 10.1016/j.gore.2017.02.001.

Lung, Respiratory and Thoracic CancerLymphoma

Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature

J Pharm Pract.

Thumallapally N, Yu H, Farhan M, Ibrahim U, Odiami M

doi: 10.1177/

Brief Report: Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first and third generation EGFR-TKIs and shifts allelic configuration at resistance

J Thorac Oncol.

Wang Z, Yang JJ, Huang J, Ye JY, Zhang XC, Tu HY, Han-Zhang H, Wu YL

doi: 10.1016/j.jtho.2017.06.017.

Lung, Respiratory and Thoracic CancerLymphoma

Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review

Onco Targets Ther.

Wang H, Zhu H, Kong L, Yu J.

doi: 10.2147/OTT.S101241.

Lung, Respiratory and Thoracic Cancer

The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations

Oncotarget.

Liu CY, Yang CT, Wang CL, Li SH, Hsu PC, Chen CH, Lin TY, Kuo CH, Fang YF, Ko HW, Yu CT, Yang TY

doi: 10.18632/oncotarget.18746.

Lung, Respiratory and Thoracic Cancer

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

Lung Cancer.

Paz-Ares LG, Pérol M, Ciuleanu TE, Kowalyszyn RD, Reck M, Lewanski CR, Syrigos K, Arrieta O, Prabhash K, Park K, Pikiel J, Göksel T, Lee P, Zimmermann A, Cuyun Carter G, Alexandris E, Garon EB

Gastrointestinal Cancer

Resectable adenocarcinoma developing in the remnant pancreas 7 years after partial pancreatoduodenectomy for invasive ductal adenocarcinoma of the pancreas: a case report

J Med Case Rep.

Frei L, Stieger R, Bayerl C, Breitenstein S, Staerkle RF

doi: 10.1186/s13256-017-1359-3.

Related content

Successful pulmonary arterial embolization followed by curative surgery for a lepidic predominant lung adenocarcinoma with severe hypoxemia

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

Metastases from lung adenocarcinoma within a leiomyoma: A case report

Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature

Brief Report: Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first and third generation EGFR-TKIs and shifts allelic configuration at resistance

Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review

The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

Resectable adenocarcinoma developing in the remnant pancreas 7 years after partial pancreatoduodenectomy for invasive ductal adenocarcinoma of the pancreas: a case report